KR20120066067A - 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법 - Google Patents

5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법 Download PDF

Info

Publication number
KR20120066067A
KR20120066067A KR1020127011980A KR20127011980A KR20120066067A KR 20120066067 A KR20120066067 A KR 20120066067A KR 1020127011980 A KR1020127011980 A KR 1020127011980A KR 20127011980 A KR20127011980 A KR 20127011980A KR 20120066067 A KR20120066067 A KR 20120066067A
Authority
KR
South Korea
Prior art keywords
lower alkyl
formula
phenyl
methyl
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127011980A
Other languages
English (en)
Korean (ko)
Inventor
조셉 맥케나
웬-충 시에
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20120066067A publication Critical patent/KR20120066067A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
KR1020127011980A 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법 Ceased KR20120066067A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US60/688,977 2005-06-09
US70559005P 2005-08-04 2005-08-04
US60/705,590 2005-08-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028638A Division KR101216249B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137025659A Division KR101514593B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Publications (1)

Publication Number Publication Date
KR20120066067A true KR20120066067A (ko) 2012-06-21

Family

ID=37091153

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127011980A Ceased KR20120066067A (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법
KR1020137025659A Active KR101514593B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법
KR1020077028638A Active KR101216249B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137025659A Active KR101514593B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법
KR1020077028638A Active KR101216249B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Country Status (31)

Country Link
US (2) US8124763B2 (enExample)
EP (1) EP1924574B1 (enExample)
JP (1) JP5118024B2 (enExample)
KR (3) KR20120066067A (enExample)
AR (1) AR053890A1 (enExample)
AT (1) ATE487709T1 (enExample)
AU (1) AU2006258051B2 (enExample)
BR (1) BRPI0611663A2 (enExample)
CA (1) CA2610105C (enExample)
CY (1) CY1111428T1 (enExample)
DE (1) DE602006018156D1 (enExample)
DK (1) DK1924574T3 (enExample)
EC (1) ECSP077982A (enExample)
EG (1) EG25039A (enExample)
GT (1) GT200600217A (enExample)
IL (1) IL187421A (enExample)
JO (1) JO2636B1 (enExample)
MA (1) MA29599B1 (enExample)
MX (1) MX2007015423A (enExample)
MY (1) MY147436A (enExample)
NO (1) NO340743B1 (enExample)
NZ (1) NZ563740A (enExample)
PE (1) PE20070015A1 (enExample)
PL (1) PL1924574T3 (enExample)
PT (1) PT1924574E (enExample)
RU (1) RU2444520C2 (enExample)
SA (1) SA06270147B1 (enExample)
SI (1) SI1924574T1 (enExample)
TN (1) TNSN07463A1 (enExample)
TW (1) TWI430999B (enExample)
WO (1) WO2006135641A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) * 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
EP1044977B1 (en) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
FR2840303B1 (fr) * 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2548078C (en) 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
RU2444520C2 (ru) 2012-03-10
HK1117524A1 (en) 2009-01-16
AU2006258051A1 (en) 2006-12-21
JP5118024B2 (ja) 2013-01-16
IL187421A (en) 2011-11-30
MX2007015423A (es) 2008-02-21
PL1924574T3 (pl) 2011-04-29
DK1924574T3 (da) 2011-02-14
TNSN07463A1 (en) 2009-03-17
NO340743B1 (no) 2017-06-12
KR20130118394A (ko) 2013-10-29
IL187421A0 (en) 2008-02-09
US8124763B2 (en) 2012-02-28
CY1111428T1 (el) 2015-08-05
SI1924574T1 (sl) 2011-02-28
PT1924574E (pt) 2011-02-08
TWI430999B (zh) 2014-03-21
EG25039A (en) 2011-07-06
US8946416B2 (en) 2015-02-03
EP1924574B1 (en) 2010-11-10
KR20080022093A (ko) 2008-03-10
MY147436A (en) 2012-12-14
AU2006258051B2 (en) 2010-09-09
US20080188656A1 (en) 2008-08-07
CA2610105C (en) 2014-03-25
JO2636B1 (en) 2012-06-17
ATE487709T1 (de) 2010-11-15
JP2008545786A (ja) 2008-12-18
NO20080157L (no) 2008-01-09
CA2610105A1 (en) 2006-12-21
EP1924574A2 (en) 2008-05-28
SA06270147B1 (ar) 2009-12-22
TW200726756A (en) 2007-07-16
MA29599B1 (fr) 2008-07-01
AR053890A1 (es) 2007-05-23
PE20070015A1 (es) 2007-02-06
GT200600217A (es) 2007-03-28
ECSP077982A (es) 2008-01-23
NZ563740A (en) 2011-03-31
KR101216249B1 (ko) 2012-12-28
US20120116081A1 (en) 2012-05-10
WO2006135641A2 (en) 2006-12-21
DE602006018156D1 (de) 2010-12-23
BRPI0611663A2 (pt) 2010-09-28
RU2007148231A (ru) 2009-07-20
KR101514593B1 (ko) 2015-04-22
WO2006135641A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
US8946416B2 (en) Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
JP2009511557A (ja) 癌の処置のためのピリミジン誘導体
FI102752B (fi) Menetelmä verenpainetta alentavien 4-alkyyli-imidatsolijohdannaisten v almistamiseksi
HU229937B1 (hu) Kondenzált azepinek mint vazopresszin agonisták, a vegyületek vagy ezek gyógyászatilag elfogadható sóinak alkalmazása gyógyszer-készítmény komponenseként vagy ennek elõállítására és a hatóanyagot tartalmazó gyógyszerkészítmény
JP2007526342A (ja) 低レベルの不純物を有するオルメサルタンメドキソミル
CN100532380C (zh) 杂环化合物和以其作为有效成分的抗恶性肿瘤药
EP0432737A1 (en) Cycloheptimidazolone compounds as angiotensin II antagonists for control of hypertension
EA010392B1 (ru) Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
CN102464652B (zh) 咪唑衍生物、制备方法及用途
CN112920167A (zh) 靶向fgfr和hdac的双靶点抑制剂及其制备方法和应用、药物组合物及药剂
CN101184748B (zh) 合成5-(甲基-1h-咪唑-1-基)-3-(三氟甲基)苯胺的方法
CN117203200A (zh) 黄嘌呤氧化酶抑制剂的制备方法
WO2012004801A1 (en) Process for imatinib mesylate
HK1117524B (en) Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
CN1291190A (zh) 5-取代的嘧啶－2－基氧基羧酸衍生物及其制法和作为内皮肽拮抗剂的用途
KR0181212B1 (ko) 비페닐 유도체 및 이의 제조방법
CN120004811A (zh) 一种新的合成2-肼基-取代嘧啶的方法
CZ298235B6 (cs) Zpusob výroby N-[5-(difenylfosfinoylmethyl)-4-(4-fluorfenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamidu
KR0181213B1 (ko) 신규 n-치환 헤테로 고리 화합물, 이의 제조방법 및 이를 함유한 약제학적 조성물
CN112341344A (zh) 一种激酶抑制剂中间体的制备方法
JPH0632782A (ja) ピラゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤
WO2008041957A1 (en) Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
JPH09208581A (ja) ピロリルベンズイミダゾール誘導体

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120509

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120608

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121105

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130529

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20121105

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130829

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130529

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140319

Appeal identifier: 2013101006354

Request date: 20130829

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130927

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130927

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130829

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130107

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20140319

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20140319

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2013101006354

Request date: 20130829

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140319

WITB Written withdrawal of application